Annovis Bio falls on planned $50 mln share sale
Brief: Annovis Bio Enters Equity Distribution Agreement With Oppenheimer
Annovis Bio Inc reports results for the quarter ended September 30 - Earnings Summary
Annovis Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Annovis Files Three New Patents For Combination Therapies Involving Buntanetap, Trulicity, And Viagra
Annovis Bio Inc expected to post a loss of 50 cents a share - Earnings Preview
Brief: Annovis Bio Secures US Patent For Buntanetap To Treat Acute Traumatic Brain Injury
U.S. STOCKS ON THE MOVE-Gulf Resources, Constellation Brands, Absci
Brief: Annovis Bio Files Patent For New Composition Of Matter For Buntanetap
Brief: Annovis Bio's Buntanetap Found Safe And Effective In High-Risk Alzheimer's Patients
Brief: Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
Annovis Bio Inc expected to post a loss of 80 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Air Products and Chemicals, Geron, PayPal
Annovis Bio plunges on mid-stage data from Alzheimer's treatment
Annovis' Alzheimer's treatment helps improve cognition in trial (updated)
Annovis Bio reports positive results in mid-stage Alzheimer’s treatment trial
U.S. STOCKS ON THE MOVE-PVH Corp, oil companies, health insurers
Annovis Bio Inc reports results for the quarter ended in December - Earnings Summary
Annovis Bio Inc expected to post a loss of $1.30 a share - Earnings Preview